There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
Aquavit will officially unveil the Dermatox and Microtox programs at the Annual American Academy of Dermatology, the world's largest dermatology conference scheduled from March 25-29, 2022, in Boston, MA
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Sputnik Light is the first component of Sputnik V
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
The investment will accelerate the overall Sarclisa development program
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Subscribe To Our Newsletter & Stay Updated
